Premier Alternatives

Sigrid Therapeutics

Sundbyberg, Sweden · Founded 2014 · Privately Held (backing)

Operator of a clinical-stage biotechnology company intended to develop a new class of therapies to prevent and treat lifestyle diseases. Sigrid Therapeutics is based in Sundbyberg, Sweden and was founded in 2014. Its last reported valuation was $40.5 million in Oct 2023. It has raised $20.9 million.

Last reported valuation
$40.5M
Oct 2026
Priced at
—
Total raised
$20.9M
Last round
—

Sigrid Therapeutics key facts

as of Oct 2026
  • Operator of a clinical-stage biotechnology company intended to develop a new class of therapies to prevent and treat lifestyle diseases.
  • Sigrid Therapeutics is valued at approximately $40.5M as of Oct 2026 (last reported valuation).
  • It has raised $20.9M; the latest was Later Stage VC ($5.0M) in Jan 2026.
  • Notable investors include Almi Invest, Joyance Partners, European Regional Development Fund (Brandenburg), Mattsson Family, The Hans and Barbara Bergström — 16 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$40.5M

Sigrid Therapeutics's last reported valuation, Oct 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Sigrid Therapeutics with a free account
  • ·The complete investor list: 16 names
  • ·Watch Sigrid Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Sigrid Therapeutics funding rounds

No rounds on record

No funding rounds for Sigrid Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Sigrid Therapeutics valuation

Sigrid Therapeutics's last reported valuation was $40.5 million in Oct 2023. No priced round, secondary trade or fund mark has surfaced since.

Sigrid Therapeutics investors

16 investors are on record for Sigrid Therapeutics, including Almi Invest, Joyance Partners, European Regional Development Fund (Brandenburg) and Mattsson Family.

About Sigrid Therapeutics

Operator of a clinical-stage biotechnology company intended to develop a new class of therapies to prevent and treat lifestyle diseases. The company has developed a novel materials platform technology that targets lifestyle diseases by altering the way the body digests food, and the product is the first therapy acting in the gut to improve blood sugar levels in individuals at risk of developing diabetes, helping patients prevent and treat modern-day chronic diseases.

Sector
Healthcare
HQ
Sundbyberg, Sweden
Founded
2014
Employees
17
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.